Loading...
5 results
Search Results
Now showing 1 - 5 of 5
- Preliminary results of an animal model validation of chronic experimental colitisPublication . Silva, Inês; Pinto, Rui; Mateus, VanessaInflammatory bowel disease (IBD): chronic inflammatory disease of the gastrointestinal (GI) tract characterized by recurrent ulceration. IBD prevalence exceeding 0,5% of the population in westernized countries. IBD manifests into several intestinal and extra-intestinal symptoms, mainly related to inflammation. IBD includes Crohn’s disease and Ulcerative colitis. Aim of the study: evaluate the efficacy of new drugs in IBD through an animal model of TNBS-induced chronic colitis.
- New pharmacological approach for inflammatory bowel diseasePublication . Silva, Inês; Pinto, Rui; Mateus, VanessaInflammatory bowel disease includes Crohn's disease and ulcerative colitis. Chronic inflammatory disease of the gastrointestinal (GI) tract is characterized by recurrent ulceration. IBD affects 7–10% of people worldwide, mainly of Caucasian descent. It manifests into several intestinal and extra-intestinal symptoms, mainly related to oxidative stress, inflammation, and autoimmune reaction. Aim of the study: evaluate the influence of a new pharmacological approach with erythropoietin in the establishment and development of inflammation associated with IBD, through of an experimental colitis model in rodents.
- TNBS-induced colitis in rodents: preliminary results of a chronic modelPublication . Silva, Inês; Solas, João; Sousa, Mariana; Modesto, Rita; Mateus, Vanessa; Pinto, RuiChronic inflammatory disease of the gastrointestinal (GI) tract characterized by recurrent ulceration. Treatment of inflammatory bowel disease induce and maintain the patient in remission However do not modify or reverse the underlying pathogenic mechanism. Nonclinical studies for emerging therapeutic strategies. Aim of the study: Evaluate the efficacy of new drugs in inflammatory bowel disease through an animal model of TNBS-induced chronic colitis.
- Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: a systematic reviewPublication . Silva, Inês; Alípio, Carolina; Pinto, Rui; Mateus, VanessaErythropoietin (EPO) is a hypoxia-induced hormone produced in adult kidneys with erythropoietic and non-erythropoietic effects. In vivo studies represent an important role to comprehend the efficacy and safety in the early phase of repurposing drugs. The aim is to evaluate the potential anti-inflammatory effect of EPO observed in animal models of disease. Following PRISMA statements, electronic database Medline via PubMed platform was used to search articles with the research expression ((erythropoietin [MeSH Terms]) AND (inflammation [MeSH Terms]) AND (disease models, animal [MeSH Terms])). The inclusion criteria were original articles, studies where EPO was administered, studies where inflammation was studied and/or evaluated, non-clinical studies in vivo with rodents, and articles published in English. Thirty-six articles met the criteria for qualitative analysis. Exogenous EPO was used in models of sepsis, traumatic brain injury, and autoimmune neuritis, with an average of 3000 IU/Kg for single and multiple doses, using mice and rats. Biomarkers such as immune-related effectors, cytokines, reactive oxygen species, prostaglandins, and other biomarkers were assessed. EPO has been recognized as a multifunctional cytokine with anti-inflammatory properties, showing its significant effect both in acute and chronic models of inflammation. Further non-clinical studies are suggested for the enlightenment of anti-inflammatory mechanisms of EPO in lower doses, allowing us to understand the translational data for humans.
- Preliminary study towards a chronic experimental model to study inflammatory bowel diseasePublication . Silva, Inês; Pinto, Rui; Mateus, VanessaInflammatory bowel disease (IBD): Chronic inflammatory disease of the gastrointestinal (GI) tract characterized by recurrent ulceration. IBD prevalence exceeding 0,5% of the population in westernized countries. IBD manifests into several intestinal and extra-intestinal symptoms, mainly related to inflammation. Aim of the study: Evaluate the efficacy of new drugs in inflammatory bowel disease through an animal model of TNBS-induced chronic colitis.